For millions of people worldwide, the APOE4 gene variant represents the most significant genetic risk factor for the development of Alzheimer’s disease. While the correlation between this gene and the eventual onset of dementia has been well-documented for decades, the precise mechanisms of how it initiates the long-term decline of cognitive health have remained shrouded in mystery. New research from the Gladstone Institutes, published in the journal Nature Aging, now suggests that this genetic variant may begin its destructive work long before memory lapses or behavioral changes become apparent to patients or their physicians.
By mapping a molecular sequence that underlies these early-stage neurological effects, the research team has identified a potential pathway for intervention. Their findings indicate that the damage caused by APOE4 may be reversible, offering a glimmer of hope that future therapies could target specific molecular triggers to prevent or delay the onset of Alzheimer’s in high-risk individuals.
A Major Genetic Risk Factor for Alzheimer’s
The APOE gene, which provides instructions for making a protein that helps carry cholesterol and other fats in the bloodstream, exists in three common forms: APOE2, APOE3, and APOE4. While APOE3 is considered the neutral or "normal" variant, APOE4 is fundamentally linked to a significantly higher risk of Alzheimer’s disease. Current estimates suggest that roughly one in four people carry at least one copy of the APOE4 variant. More striking is its prevalence among the Alzheimer’s population, where it is estimated to be present in 60 to 75 percent of all cases.
Despite this well-established link, the medical community has struggled to pinpoint exactly how the gene influences the brain’s circuitry. Dr. Yadong Huang, associate director of the Gladstone Institute of Neurological Disease and a senior author of the study, characterizes these new findings as a landmark breakthrough. "It opens the door to a better understanding of how APOE4 alters the function of neurons at a young age to increase the risk of cognitive decline," Dr. Huang explains, noting that the study provides a concrete framework for developing therapies that could block these detrimental effects before they manifest as clinical symptoms.
APOE4 Makes Memory Circuits Hyperactive Early
The research team, led by scientists at Gladstone, focused their investigation on the hippocampus—the area of the brain primarily responsible for learning and memory. Previous studies had observed signs of unusual hyperactivity in the brains of human APOE4 carriers long before they reached middle age. This early-stage hyperexcitability has long been suspected as a precursor to eventual cognitive decline, but the "why" and "how" remained elusive.
To uncover the mechanism, the researchers utilized advanced recording techniques to monitor brain activity in young mice carrying the APOE4 variant. Their observations revealed excessive neuronal firing within two distinct regions of the hippocampus. Crucially, the researchers noted that the severity of this early-life hyperactivity directly correlated with later cognitive performance. As Dr. Dennis Tabuena, a scientist co-mentored by Dr. Huang and Dr. Misha Zilberter and the study’s first author, explains: "We found that the extent of hyperactivity in young mice predicted how poorly they performed on spatial learning and memory tests later in life."
This hyperactive state appears to be linked to structural changes in the neurons themselves. When compared to mice carrying the APOE3 variant, the neurons in the APOE4 mice were physically smaller. In the world of neurobiology, smaller neurons are generally more sensitive to stimulation, making them inherently more likely to fire excessively. While the researchers noted that APOE3 mice also experienced an increase in neuronal excitability, this transition did not occur until the animals reached old age. The evidence suggests that APOE4 essentially puts the brain on an accelerated aging trajectory, which may explain why carriers of this variant are statistically more likely to develop Alzheimer’s disease at an earlier age.
The Effect Comes From APOE4 Inside Neurons
One of the most surprising aspects of this research is its challenge to long-held assumptions about where the damage originates. For years, the scientific community believed that astrocytes—the star-shaped cells that provide support and structural integrity to neurons—were the primary culprits in the APOE4-Alzheimer’s connection. Because astrocytes are the main producers of APOE in a healthy brain, it was widely assumed that they were responsible for the subsequent dysfunction observed in neurons.
The Gladstone team’s findings, however, point in an entirely different direction. By systematically manipulating the expression of the gene, the researchers discovered that the hippocampal hyperactivity associated with APOE4 is driven specifically by the APOE4 protein produced within the neurons themselves.
"When we deleted the APOE4 gene from astrocytes, nothing changed," notes Dr. Misha Zilberter, a principal staff research scientist at Gladstone and a senior author of the study. "But when we deleted it from neurons, the cells became larger and started functioning normally again." This distinction is critical, as it shifts the focus of future therapeutic development from supporting glial cells to addressing the internal regulatory processes of the neurons themselves.
Nell2 Emerges as a Possible Treatment Target
In their search for the specific molecular pathway responsible for these changes, the researchers performed an extensive analysis of gene activity within individual cells across the hippocampus. This process identified a protein known as Nell2 as a key player. In APOE4 carriers, Nell2 levels were found to be significantly higher than normal.
To test whether this protein was indeed the driver of the dysfunction, the researchers employed CRISPRi—a gene-silencing technology that allows for the temporary reduction of gene expression without altering the underlying DNA. When they lowered the production of Nell2 in the hippocampal neurons of adult mice, the results were transformative. The neurons not only returned to their normal, larger size but also regained their healthy firing behavior, losing the pathological excitability that had characterized their early development.
This discovery is particularly compelling because it suggests that the cognitive damage caused by APOE4 is not a one-way street. "What’s exciting about Nell2 is that we were able to reverse the disease manifestations in adult mice by lowering its level," says Dr. Huang. "That tells us the damage is not irreversible, and that there may be a window for intervention even after disease processes have been triggered."
While Nell2 has not been a primary focus of Alzheimer’s research in the past, its elevated presence in the brains of human Alzheimer’s patients—and its link to lower cognitive scores—suggests that this protein could be a viable target for future drug development. By providing a clear target for intervention, this research offers a new strategy for managing the risk faced by millions of people who carry the APOE4 gene.
As the team continues to explore the molecular interactions between APOE4 and Nell2, the focus remains on the implications for human health. Dr. Zilberter emphasizes the importance of this timing: "To the best of our knowledge, this is the first study that has directly examined what APOE4 does to the function of neurons at different ages. We found fundamental changes in brain circuits occurring in young mice that still had normal learning and memory, and importantly, that those changes predicted the development of cognitive deficits at older ages."
By identifying the early molecular markers of Alzheimer’s, researchers are moving closer to a future where high-risk patients can be identified and treated long before the clinical manifestations of the disease take hold. The work, which received support from several institutions including the National Institute on Aging and the National Institute of Neurological Disorders and Stroke, serves as a vital step forward in the ongoing quest to turn the tide against Alzheimer’s disease.
